Ghiselli G, Gotto A M, Tanenbaum S, Sherrill B C
Proc Natl Acad Sci U S A. 1985 Feb;82(3):874-8. doi: 10.1073/pnas.82.3.874.
We have determined the turnover rates for proapolipoprotein A-I (proapoA-I) and mature apolipoprotein A-I (apoA-I) in vivo in human and in rat. For the human study, high density lipoprotein (HDL)-associated 125I-labeled proapoA-I (A-I isoform 1) and 131I-labeled mature apoA-I (A-I isoforms 3, 4, and 5) were injected simultaneously into two normal volunteers. Blood samples were obtained serially and HDL proapoA-I and mature apoA-I were separated by isoelectrofocusing for the determination of the associated radioactivity. Residence times of proapoA-I and mature apoA-I were 0.13 and 3.9 days and production rates were 9.0 and 9.3 mg/kg per day, respectively. Analysis of the specific activity curves suggested a complete proapoA-I to mature apoA-I precursor-product relationship. Proprotein conversion was virtually completed in 24 hr. For the rat study, HDL- and lymph chylomicron- (flotation constant Sf greater than 400 S) associated 125I-labeled proapoA-I and 131I-mature apoA-I were injected into fasted rats. Residence times of proapoA-I and mature apoA-I injected in association with HDL were 0.13 and 0.28 day, respectively, and for injection associated with chylomicrons the residence times were 0.08 and 0.26 day. When associated with chylomicrons, proapoA-I was converted more efficiently to the mature form. As in the human study, the results demonstrated a complete proapoA-I to mature apoA-I precursor-product relationship. Our data are consistent with the concepts that (i) conversion to mature apoA-I is the major proapoA-I catabolic fate in plasma; (ii) mature apoA-I is conceivably derived solely from proapoA-I in plasma and proapoA-I is the major apoA-I form secreted in vivo; and (iii) a putative proapoA-I-chylomicron complex is the preferred substrate for the apoA-I propeptidase.
我们已经测定了人及大鼠体内前载脂蛋白A-I(proapoA-I)和成熟载脂蛋白A-I(apoA-I)的转换率。在人体研究中,将与高密度脂蛋白(HDL)相关的125I标记的proapoA-I(A-I同工型1)和131I标记的成熟apoA-I(A-I同工型3、4和5)同时注射到两名正常志愿者体内。连续采集血样,通过等电聚焦分离HDL proapoA-I和成熟apoA-I,以测定相关放射性。proapoA-I和成熟apoA-I的停留时间分别为0.13天和3.9天,生成率分别为每天9.0毫克/千克和9.3毫克/千克。对比活度曲线的分析表明proapoA-I与成熟apoA-I之间存在完整的前体-产物关系。前体蛋白的转化在24小时内基本完成。在大鼠研究中,将与HDL及淋巴乳糜微粒(漂浮常数Sf大于400 S)相关的125I标记的proapoA-I和131I标记的成熟apoA-I注射到禁食的大鼠体内。与HDL相关注射的proapoA-I和成熟apoA-I的停留时间分别为0.13天和0.28天,与乳糜微粒相关注射的停留时间分别为0.08天和0.26天。当与乳糜微粒相关时,proapoA-I更有效地转化为成熟形式。与人体研究一样,结果表明proapoA-I与成熟apoA-I之间存在完整的前体-产物关系。我们的数据与以下概念一致:(i)转化为成熟apoA-I是血浆中proapoA-I的主要分解代谢命运;(ii)成熟apoA-I可以想象仅来源于血浆中的proapoA-I,且proapoA-I是体内分泌的主要apoA-I形式;(iii)假定的proapoA-I-乳糜微粒复合物是apoA-I前肽酶的首选底物。